First-line trials

These trials are for patients that have never had Gleevec before (although some may allow previous adjuvant Gleevec, check the trial details). The intent of these trials is to try to improve on the initial response to therapy. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

5 trials found

Guadecitabine

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Phase: 
2 Drug Category: SDH-directed
NCT#:
NCT03165721 Conditions: SDH- GIST
Status:
Recruiting
Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA


Imatinib

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT01541709 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea


Imatinib + Regorafenib

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor + VEGF inhibitor
NCT#:
NCT02365441 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Calvary Mater Newcastle Hospital Waratah New South Wales Australia
Prince of Wales Hospital Randwick New South Wales Australia
Princess Alexandra Hospital Woolloongabba Queensland Australia
Ashford Cancer Centre Research Kurrulta Park South Australia Australia
Flinders Medical Centre Bedford Park South Australia Australia
Canberra Hospital Garran Australian Capital Territory Australia
Sir Charles Gairdner Hospital Nedlands Western Australia Australia
Royal Hobart Hospital Hobart Tasmania Australia
Border Medical Oncology Wodonga Victoria Australia
Peninsula South Eastern Haematology & Oncology Group Frankston Victoria Australia
Norwegian Radium Hospital Oslo Norway
National Cancer Center Singapore Singapore
Helsinki University Central Hospital Helsinki Finland
Institut Bergonie Bordeaux Gironde France
Centre Georges Francois Leclerc Dijon France
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
Dept of Oncology, Haukeland University Hospital Bergen Norway
Norwegian Radium Hospital Oslo Norway
Lund University Hospital Lund Sweden
CO L'Hospitalet - Hospital Duran i Reynals Barcelona Spain
National Cancer Institute Bratislava NSW Slovakia
Royal Marsden Hospital - Chelsea London UK
University Hospital Birmingham - Queen Elizabeth Hospital Birmingham UK
Nottingham University Hospitals NHS Trust - Nottingham City Hospital Nottingham UK


Selumatinib

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Phase: 
2 Drug Category: NF1 GIST
NCT#:
NCT03109301 Conditions: NF1 GIST
Status:
Recruiting
Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA


Temozolomide

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase: 
2 Drug Category: Chemotherapy
NCT#:
NCT03556384 Conditions: SDH Deficient GIST
Status:
Recruiting
Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA


5 trials found